

A Prospective Policy Analysis of HIV/AIDS Policies in Japanese Multinational Corporations in Asia

Ryoko Michinobu, PhD, MPH, MA, School of Health Sciences, Sapporo Medical University, JAPAN

Presented at the 135th Annual Meeting and Exposition of the American Public Health Association, Washington, DC, November 3-7, 2007

1. Purpose

The purpose of this study was to examine the present state of corporate HIV/AIDS policies among Japanese multinational corporations (MNCs) in Asian countries, with a special focus on those operating in northern Thailand

This study aimed to offer a set of policy options for corporate HIV/AIDS policies in Japanese MNCs, based on the understanding of the reasons why policies endorsed by international organizations had not been successfully transferred to Japanese MNCs.


2. Background

Poor corporate responses to HIV/AIDS among Japanese companies

- 1. The first descriptive survey on the corporate attitudes and practices of Japanese companies regarding HIV/AIDS measures, targeted at 1.655 companies listed on the Tokyo Stock Exchange as of April 1993, found that only 7% of the respondent companies (the response rate was 38%) had policies related to HIV/AIDS and only 5% of the companies were developing them. It also found that 36.8% of the companies had implemented some measures (Muto, Fukuwatari & Onoda, 1996)
- 2. A study of corporate reports of Japanese companies listed in the First Section of the Tokyo Stock Exchange in November 2004 found that only 1% of the companies that published corporate reports mentioned HIV/AIDS (Kawashita et al., 2005)

Lack of social responses to HIV/AIDS and rising HIV cases in Japan


Figure 1 HIV/AIDS-related newspaper articles by year of reporting in three national Japanese newspapers and reported HIV cases in Japan, 1987-2004



between contaminated blood products and the outbreak of HIV/AIDS came to light and HIVinfected hemophilia: patients successively filed lawuits against the Ministry of Health and Welfare (MHW) and five pharmaceutical companies. But the public interest latter place latter per settlement agreement between the hem Hey and the patients, and the level of interest remains low.

Prospects of Japanese Direct Investment and HIV/AIDS in Asia Table 1 HIV/AIDS statistics and Japanese direct investment by region 2005





Acknowledgements

This study is supported by a Grants-in-Aid for Scientific

Education, Culture, Sports, Science and Technology of Japan.

Hubert Department of Global Health, Emory University. I

for his valuable suggestions and guidance, and the study

participants who made this poster presentation possible


This poster presentation is based on my thesis submitted to the

wish to thank both Professor Roger Rochat, my thesis advisor,

Research (Grant No. 17611004) from the Ministry of



those inside the company



The ILO Code of Practice on

HIV/AIDS and the World of Work

policies and programs that address the HIV/AIDS epidemic in the workplace.

Providing global guidelines for developing

 Covering four key areas of action: prevention of HIV/AIDS, management and mitigation of the impact of HIV/AIDS, care and support,

and elimination of stigma and discrimination Expecting the workplace policies and

programs to reach beyond the workplace to include former employees, dependents, communities, suppliers and contractors,

- Expecting partnerships with the wider society.

through community outreach or family-

Articulating 10 principles of action

ILO's 10 principles

Healthy work envir

No screening for purp

Confidentiality

The global standards were not shared among Japanese MNCs, and large policy gaps existed. HIV/AIDS activities were centered on information provision, awareness raising activities and condom distribution for their workers: further actions were not carried out except for philanthropic activities Japanese companies lacked a system of HIV/AIDS management that enables policy formulation and implementation both at the level of headquarters as well as at the level of affiliated companies. Japanese management did not have an incumbent concern about the issue of HIV/AIDS in the workplace, nor did they participate in partnerships. There are potential risks of HIV infection among workers of the case companies HIV/AIDS-related activities by outside organizations did not successfully change workers' risk perception and behavior. Policy options · Mainstreaming HIV/AIDS into occupational safety and health management (OSHM) Developing HIV/AIDS policy and measures as elements of the group-wide OSHM so that the company can respond to HIV/AIDS systematically and consistently. Developing comprehensive policy and measures that can be expanded · Capacity building of individual employees with the help of supportive community activities Developing community-based actions to empower local workers - Strengthening the role of safety committees to bring up the concerns of ordinary workers to management Capacity building of corporations within supportive social and policy environment Developing multisectoral partnerships among the Ministry of Health, Labour and Welfare; the Friends of the Global Fund, Japan; and the Nippon Keidanren (Japan Business Federation) HIV/AIDS polic Corporate behavioral

5. Discussion and Conclusions

Contact Information

School of Health Sciences, Email michinor@sapmed.ac.ip

Ryoko Michinobu, PhD, MPH, MA Sapporo Medical University, JAPAN Phone +81-11-611-2111 ext. 2833